Is intra-arterial chemotherapy useful in high-grade gliomas?

References

• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 35, 1011–1018 (2002).
   Google Scholar
• ••A recent meta-analysis on individualpatient data collected from 12 randomized trials, for a total of more than 3000 high-grade glioma patients, demonstrating that chemotherapy achieves a modest but statistically highly significant, increase in survival (6% absolute increase at 1 year).
   Google Scholar
• Brandes AA, Basso U, Pasetto LM, Ermani M. New strategy developments in brain tumor therapy. CUI7: Pharm. Des.7, 1553–1580 (2001).
   Google Scholar
• Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanism in the brain, I. adult brain. Clin. Expel: Pharmacol. Physiol. 26, 11–19 (1999).
   Google Scholar
• Groothius DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neurooncol. 2, 45–59(2000).
   Google Scholar
• •A detailed review on the pharmacological properties of the blood—brain barrier (BBB) and of the possible mechanisms to circumvent it in order to enhance chemotherapy delivery to the brain.
   Google Scholar
• French JD, West PM, Von Armerongen FK et al Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. .1. Neurosurg. 9, 378–384 (1952).
   Google Scholar
• Hochberg FH, Pruitt AA, Beck DO, DeBrun G, Davis K. The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. I Neumsurg. 63, 876–880 (1985).
   Google Scholar
• •Relevant discussion on the rationale and methods of intra-arterial BCNU administration.
   Google Scholar
• Recht L, Pram RJ, Strauss G et al Pre-irradiation chemotherapy of supratentorial malignant primary bran tumors with intracarotid cisplatinum and IV BCNU. Am.j Gun. Onco1.13, 125–131 (1990).
   Google Scholar
• Dropcho EJ, Rosenfeld SS, Morawetz RB et al. Pre-radiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas.j Gun. Dna. 10, 452–459 (1992).
   Google Scholar
• Brandes AA, Rigon A, Zampieri P et al Early chemotherapy and concurrent radiochemotherapy in high-grade glioma. Neurooncol 30, 247–255 (1996).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Gobin YP, Black KL et al Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J. Neumoncol 35, 121–131 (1997).
   PubMed Web of Science ®Google Scholar
• •An interesting report showing that calculating intra-arterial carboplatin doses according to cerebral blood flow and site of injection reduces the overall incidence of treatment-related toxicities.
   Google Scholar
• Blacklock JB, Wright DC, Dedrick RL et al Drug streaming during intra-arterial chemotherapy. J. Neurosurg: 64, 284–291 (1986).
   PubMed Web of Science ®Google Scholar
• Saris SC, Blasberg RG, Carson RE et al Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J. Neurosurg. 74, 763–770 (1991).
   Google Scholar
• Bobo H, Kapp JP, Vance R. Effect of intra- arterial cisplatin and 1,3-bis(2chloroethy0-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation] Neu/vaned. 13, 291–299 (1992).
   Google Scholar
• Rosenblum MK, Delattre JY, Walker RVV et al Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intrarterial BCNU and irradiation: a pathological study. J. Neurooncol 7, 269–274 (1989).
   PubMed Web of Science ®Google Scholar
• Bashir R, Hochberg PH, Lingwood R et al Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. I Neurosurg. 68, 917–923 (1988).
   PubMed Web of Science ®Google Scholar
• Fauchon F, Davila L, Chatellier G et al. Treatment of malignant gliomas with surgery, intra-arterial infusions of 1-(2-hydroxyethy0 chloroethylnitrosourea and radiation therapy: a Phase II study. Neurosurgery27, 231–234 (1990).
   PubMed Web of Science ®Google Scholar
• Feun LG, Wallace S, Stewart DJ et al Intracarotid infusion of Cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54, 794–799 (1984).
   PubMed Web of Science ®Google Scholar
• Mahaley MS Jr, Hipp SW, Dropcho EJ et al Intracarotid cisplatin chemotherapy for recurrent gliomas. I Neurosurg. 70, 371–378 (1989).
   PubMed Web of Science ®Google Scholar
• Greenberg HS, Ensminger WD, Chandler WF et al. Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J. Neurosurg. 61, 423–429 (1984).
   PubMed Web of Science ®Google Scholar
• Gebarski SS, Greenberg HS, Gabrielsen TO, Vine AK. Orbital angiographic changes after intracarotid BCNU chemotherapy. AJNR Am J. Neurorachol 5, 55–58 (1984).
   PubMed Web of Science ®Google Scholar
• Assietti R, Olson JJ. Intra-arterial cisplatin in malignant brain tumors: incidence and severity of ototoxicity. I Neumoncol 27, 251–258 (1996).
   PubMed Web of Science ®Google Scholar
• Yamada K, Ushio Y, Hayakawa T et al Distribution of radio-labeled 1-(4-amino-2-methyl 1-5-pyrimidiny0 methyl 3 (2 chloroethy0 3-nitrosourea hydrochloride in rat brain tumor: intra-arterial versus iv. administration. Cancer Res. 47, 2123–2128 (1987).
   Google Scholar
• Bullard DE, Bigner SH, Bigner DD. Comparison of iv. versus intracarotid therapy with 1,3-bis (2-chloroethy0-1-nitrosourea in a rat brain tumor model. Cancer Res. 45, 5240–5245 (1985).
   Google Scholar
• Brandes AA, Basso U, Pasetto LM. Changing boundaries in the treatment of malignant gliomas. Exp. Rev Anticancer Ther 1(3), 357–370 (2001).
   Google Scholar
• •A thorough review on recent accomplishments and current avenues of research in the field of medical treatment for high-grade gliomas.
   Google Scholar
• Clayman DA, Wolpert SM, Heros DO. Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas. AJNR Am. J. Neurorachol 10, 767–771 (1989).
   Google Scholar
• Bradac GB, Soffietti R, Riva A, Stura G, Sales S, Schiffer D. Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas. Neurorachology34, 73–76 (1992).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Green SB, Burger PC et al A randomized comparison of intra-arterial versus iv. BCNU, with or without iv. 5-fluorouracil, for newly diagnosed patients with malignant glioma. I Neumsurg 76, 772–781 (1992).
   Google Scholar
• ••The unique randomized trial on infra-arterial BCNU chemotherapy, showing no superiority of the intra-arterial route and the lack of efficacy of the addition of intravenous 5-fluorouracil.
   Google Scholar
• Gundersen S, Lote K, Watne K. A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in Grade 3 and 4 gliomas. Eur I Cancer 34, 1565–1569 (1998).
   Google Scholar
• Brandes A, Fiorentino M. Treatment of high-grade gliomas in the elderly. Oncology 55, 1–6 (1998).
   PubMed Web of Science ®Google Scholar
• Vega F, Davila L, Chatellier G et al Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy. J. Neumoncol 13, 131–135 (1992).
   PubMed Web of Science ®Google Scholar
• Hirano Y, Mineura K, Mizoi K et al. Therapeutic results of intra-arterial chemotherapy in patients with malignant glioma. Int.I Oncol 13, 537–542 (1998).
   PubMed Web of Science ®Google Scholar
• Kochi M, Kitamura I, Goto T et al Randomized comparison of intra-arterial versus iv. infusion of ACNU for newly diagnosed patients with glioblastoma. Neumoncol 49, 63–70 (2000).
   Google Scholar
• •Randomized trial comparing intra-arterial versus intravenous ACNU administration that found no significant differences in survival and toxicity
   Google Scholar
• Paccapelo A, Piana C, Rychlicki F et al. Treatment of malignant gliomas: a new approach. Tumor] 84, 529–533 (1998).
   PubMed Web of Science ®Google Scholar
• Ginos JZ, Cooper AJ, Dhawan V et al Cisplatin PET to assess pharmacokinetics of intra-arterial versus iv. chemotherapy for malignant brain tumors. J. Nucl. Merl 28, 1844–1852 (1987).
   Google Scholar
• Lehane DE, Bryan RN, Horowitz B et al Intra-arterial cisplatinum chemotherapy for patients with primary and metastatic brain tumors. Cancer Drug. Del 1, 69–77 (1983).
   PubMedGoogle Scholar
• Newton FIB, Page MA, Junck L, Greenberg HS. Intra-arterial cisplatin for the treatment of malignant gliomas. Neurooncol 7, 39–45(1989).
   PubMed Web of Science ®Google Scholar
• Tfayli A, Hentschel P, Madajewicz S et al Toxicities related to intra-arterial infusion of cisplatin and etoposide in patients with brain tumors. J. Neurooncol 42, 73–77 (1999).
   PubMed Web of Science ®Google Scholar
• •Thorough analysis of incidence and severity of side effects of intra-arterial cisplatin administration in 168 patients.
   Google Scholar
• Hiesiger EM, Green SB, Shapiro WR et al Results of a randomized trial comparing intra—arterial cisplatin and iv. PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. I Neurooncol 25, 143–154 (1995).
   Google Scholar
• •Randomized trial proving no superiority of intra-arterial cisplatin compared with intravenous administration of the nitrosourea PCNU; higher neurological toxicity was encountered in the cisplatin arm, while myelotoxicity was prevalent in the PCNU arm.
   Google Scholar
• Tamaki M, Ohno K, Niimi Y et al Parenchymal damage in the territory of the anterior choroidal artery following supraophthalmic intracarotid administration of CDDP for treatment of malignant gliomas. I Neurooncol 35, 65–72 (1997).
   PubMed Web of Science ®Google Scholar
• Spigelman MK, Zappulla RA, Strauchen JA et al Etoposide induced blood—brain barrier disruption in rats: duration of opening and histological sequelae. Cancer Res. 46, 1453–1457 (1986).
   PubMed Web of Science ®Google Scholar
• Madajewicz S, Chowhan N, Tyfali A et al. Therapy for patients with high-grade astrocytoma using intrarterial chemotherapy and radiation therapy. Cancer88, 2350–2356 (2000).
   PubMed Web of Science ®Google Scholar
• Ashby LS, Shapiro WR. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a Phase II study. I Neumoncol 51, 67–86 (2001).
   PubMed Web of Science ®Google Scholar
• •Authors present their experience on infra-arterial cisplatin plus oral etoposide administration along with a retrospective analysis on published trials on infra-arterial/intravenous cisplatin with or without etoposide and conclude that infra-arterial cisplatin administration is not warranted.
   Google Scholar
• Doz F, Berens ME, Dougherty DV, Rosenblum ML. Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. I Neurooncol 11, 27–35 (1991).
   PubMed Web of Science ®Google Scholar
• Follezou JY, Fauchon F, Chiras J. Infra- arterial infusion of carboplatin in the treatment of malignant gliomas: a Phase II study. Neoplasma 36, 349–352 (1989).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Belanger JM, Grahovac Z et al Phase I study of intracarotid administration of carboplatin. Neurosurgery30, 512–516 (1992).
   PubMed Web of Science ®Google Scholar
• Dropcho EJ, Rosenfeld SS, Vitek J, Guthrie BL, Morawetz RB. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. I Neurooncol 36, 191–198 (1998).
   Google Scholar
• Lamer JM, Kersh CR, Constable WC et al Phase Jill trial of superselective arterial 5-FU infusion with concomitant external beam radiation for patients with either anaplastic astrocytoma or glioblastoma multiforme. AM. I Clin. awl 14, 514–518 (1991).
   Google Scholar
• Kroll RA, Neuwelt EA. Outwitting the blood—brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42, 1083–1099 (1998).
   PubMed Web of Science ®Google Scholar
• •Review on the rationale and mechanisms of BBB disruption in order to increase the uptake of therapeutic drugs.
   Google Scholar
• Williams PC, Henner WD, Roman- Goldstein S et al Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood—brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37,17–27 (1995).
   PubMed Web of Science ®Google Scholar
• Hiesiger EM, Voorhies RM, Basler GA, Lipschutz LE, Posner JB, Shapiro WR. Opening the blood—brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann. Neural 19, 50–59 (1986).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Grahovac Z, Hugenholtz H et al Feasibility study of intrarterial vs. iv. cisplatin, BCNU and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. Neurooncol 17, 71–79 (1993).
   Google Scholar
• Neuwelt EA, Howieson J, Frenkel EP et al Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood—brain barrier modification in glioblastoma. Neurosurgery 19, 573–582 (1986).
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Namba H, Saegusa T, Sueyoshi K. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors. J. Neurooncol 15, 185–193 (1993).
   PubMed Web of Science ®Google Scholar
• •Randomized trial comparing intra-arterial administration of ACNU and Cisplatin with or without BBB disruption with mannitol, reporting a modest increase in survival but below the significance level.
   Google Scholar
• Doolittle ND, Miner ME, Hall WA et al Safety and efficacy of a multicenter study using intrarterial chemotherapy in conjunction with osmotic opening of the blood—brain barrier for the treatment of patients with malignant brain tumors. Cancer88, 637–647 (2000).
   PubMed Web of Science ®Google Scholar
• •A multicenter trial on BBB disruption with mannitol followed by a combination of intra-arterial and intravenous chemotherapy in patients with a wide range of brain tumors, showing that this procedure is safe and reproducible across multiple centers.
   Google Scholar
• Cloughesy TF, Black KL. Pharmacological blood—brain barrier modification for selective drug delivery. I Neurooncol 26, 125–132 (1995).
   PubMed Web of Science ®Google Scholar
• Bartus RT, Elliot PJ, Dean RL et al Controlled modulation of BBB permeability using the bradykinin against, RA4P-7. Exp. Neural 142, 14–28 (1996).
   Google Scholar
• •Detailed description of the pharmacological properties of the bradykinin analog R.1\413–7.
   Google Scholar
• Emerich DF, Dean RL, Snodgrass P et al Bradykinin modulation of tumor vasculature: II. Activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. Pharmacol Exp. Thar. 296, 632–641 (2001).
   Google Scholar
• Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW Pathway across blood—brain barrier opened by the bradykinin agonist, RMP-7. Brain Res. 705, 125–135 (1995).
   PubMed Web of Science ®Google Scholar
• Emerich DF, Dean RL, Marzh J. Intravenous cereport (RNIP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharm. Res. 17,1219-1219 (2000).
   Google Scholar
• Black KL, Cloughesy T, Huang SC et al Intracarotid infusion of RWIP-7, a bradykinin analog and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. I Neurosurg. 86,603–609 (1997).
   PubMed Web of Science ®Google Scholar
• Emerich DF, Snodfrass P, Kean R et al Enhanced delivery of carboplatin into brain tumours with iv. Cereport (RNIP-7): dramatic differences and insight gained from dosing parameters. BE J Cancer 80, 964–970 (1999).
   Google Scholar
• Matsukado K, Nakano S, Bartus RT et al Steroids decrease uptake of carboplatin in rat gliomas — uptake improved by intracarotid infusion of bradykinin analog, RMP-7. I Neurooncol 34,131–138 (1997).
   PubMed Web of Science ®Google Scholar
• Black KL, Cloughesy T, Huang SC et al Intracarotid infusion of RWIP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. I Neurosurg. 86,603–609 (1997).
   PubMed Web of Science ®Google Scholar
• Gregor A, Lind M, Newman H et al Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high-grade glioma. Neurooncol 44,137–145 (1999).
   PubMed Web of Science ®Google Scholar
• Chow KL, Gobin YP, Cloughesy TF, Sayre JW, Villablanca JP, Vinuela E Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intrarterial chemotherapy. AJNR Am. J Neuroracliol 21,471–478 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas HD, Lind MJ, Ford J, Bleehen N, Calver AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist cereport (RIVW-7) for the treatment of brain tumours. Cancer Chemother. Pharmacol 45, 284–290 (2000).
   Google Scholar
• Yang W, Barth RF, Bartus RT et al Improved survival after boron neutron capture therapy of rain tumors by cereport-mediated blood—brain barrier modulation to enhance delivery of boronophenylalanine. Aiumsurge ry47, 189–197 (2000).
   Google Scholar
• LeMay DR, Kittaka M, Gordon EM et al Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy. Hum. Gen. Thar. 9,989-995 (1998).
   Google Scholar
• Qureshi Pd, Sun i MFK, Khan J et al Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. J. Neumoncol 51,151–158 (2001).
   Google Scholar